The improved biopharmaceutical drug Enlituo produced by Taizhou Mabtech Pharmaceutical Co Ltd – based in the Taizhou Medical High-tech Zone in Taizhou city, in East China's Jiangsu province – recently began clinical use.
In 2015, Hong Kong-based Mabpharm Limited founded Taizhou Mabtech Pharmaceutical Co in Taizhou, focusing on the research and commercialization of new drugs and biosimilars for cancer and autoimmune diseases.
The clinical use of Enlituo is said to mark that the drug has officially benefited colorectal cancer patients on the Chinese Mainland.
Enlituo's journey to the market has undergone more than 20 years of R&D – using internationally authorized PCT patent technology, combined with independent intellectual property rights to prepare glycosylation modifications that are closer to humans.
The medicine is expected to significantly reduce the risk of severe drug allergies in patients.
It has received support from China's 863 program, 973 program and major new drug development funds.
Listed on the Hong Kong Stock Exchange in 2019, Taizhou Mabtech Pharmaceutical Co became the first listed pharma company in China Medical City in Taizhou.
The premises of Mabpharm Limited. [Photo/Taizhou Medical High-tech Zone via WeChat weigg6666]